Rising Stars in Dermatology Conference 2027

A dedicated educational forum designed to help early-in-practice Canadian dermatologists gain meaningful insights into the management of dermatologic diseases

Saturday, April 24, 2027 • In-person

Secure your spot

Countdown to the event

Days
Hours
Minutes
Seconds

Secure Your Spot Today

Only 50 spots available

Designed for early-in-practice Canadian dermatologists
Limited travel grants available
Early registration is recommended

Registration closes March 20, 2027

Register now

The 2027 Rising Stars in Dermatology Conference will serve a foundational role in helping early-in-practice Canadian dermatologists gain meaningful insights into patient and disease management across a range of dermatologic diseases.

Conference Objectives:

  • Provide specific, high-quality information on the latest developments in dermatologic disease management, emerging therapies, and pipeline updates relevant to the Canadian market.
  • Create collegial learning opportunities and provide guidance to help early-in-practice dermatologists integrate key learnings into their clinical practice.
  • Facilitate the sharing of knowledge and experience among delegates and representatives.
  • Address the career and practice management questions of early-in-practice dermatologists.

Saturday, April 24, 2027
8:30 AM – 4:30 PM

OMNI King Edward Hotel,
Toronto, ON

Registration closes
March 20, 2027

Scientific Steering Committee
Faculty

Agenda

Morning Sessions

Risen Star Plenary Lecture
Speaker: Dr. Ron Vender


Sponsored Breakfast Symposium
TBD


Updates on the Management and Assessment of PsO in 2027
Speaker: Dr. Sabrina Nurmohamed


Updates on the Management and Assessment of AD in 2027
Speaker: Dr. Carolyn Jack


Networking Break


Updates on the Management and Assessment of CSU in 2027
Speaker: Dr. Elena Netchiporouk


Updates on the Management and Assessment of Vitiligo and Alopecia Areata in 2027
Speaker: Dr. Reetesh Bose


Updates on the Management and Assessment of Acne/Rosacea in 2027
Speaker: Dr. Toni Burbidge

Sponsored Lunch Symposium
TBD


Lunch
All


Sponsored Lunch Symposium
TBD

Blistering Skin Disease in 2027
Speaker: Dr. Alexandre Lemieux


Considerations for the Management of IMIDs in Pregnancy
Speakers: Dr. Annie Genois and Dr. Genevieve Genest


Networking Break


Considerations for the Management of IMIDs in Pediatrics
Speaker: Dr. Cathryn Sibbald


Updates on the Management and Assessment of HS in 2027
Speaker: Dr. Danya Traboulsi


Melanoma and Non-Melanoma Assessment and Management in 2027
Speaker: Dr. Max Sauder

Meet your sponsors

Gold Level
Arcutis Canada, Inc. is a subsidiary of Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune‐mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio that harnesses our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, and alopecia areata.
Bausch Health, Canada Inc., headquartered in Laval, Quebec, is part of Bausch Health Companies Inc. (NYSE/TSX: BHC), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health\ outcomes. Bausch Health, Canada Inc. is a leader in the medical dermatology market in Canada and provides treatments for chronic weight management, allergy, neuroscience, and cardio-metabolic conditions. Our two manufacturing facilities in Canada are for prescription pharmaceuticals, including many of our leading dermatological products. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees, and investors.
Incyte is a global biopharmaceutical company focused on developing innovative therapies across oncology and inflammation and autoimmunity. Driven by strong research and scientific discovery, Incyte is committed to addressing serious unmet medical needs and improving patient outcomes worldwide.
Silver Level
Research and innovation are the cornerstones of our business. We focus on discovering, developing, and delivering drugs in therapeutic areas where we have proven expertise—and can make an impact. This includes Immunology, Oncology, Neuroscience and Virology, Women’s health, and General medicine.
Lilly is a global medicine company advancing life-changing treatments across diabetes, obesity, Alzheimer’s disease, immune disorders, and cancer. With nearly 150 years of innovation, its medicines support over 51 million people worldwide, including through its Canadian affiliate established in collaboration with the University of Toronto.
Inspired by patients and driven by science, UCB Canada is a biopharmaceutical company with a long-standing commitment to delivering life-changing medicines to Canadian patients living with severe disease – now, and in the future.
Bronze Level
Galderma is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story.
LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital.
Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women’s Health and General Medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately, or differently affect women, while expanding access to essential treatments for all in over 140 markets. Headquartered in Jersey City, New Jersey, Organon is committed to advancing access, affordability, and innovation in healthcare.
Pfizer Canada ULC is the Canadian operation of Pfizer Inc., one of the world’s leading biopharmaceutical companies. At Pfizer, we apply science and our global resources to bring therapies to people that help extend and improve their lives. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products. Our diversified health care portfolio includes some of the world’s best known and most prescribed medicines and vaccines.
At Sanofi, we chase the miracles of science to improve people’s lives. Our determination to find answers for patients motivates us to develop breakthrough medicines and vaccines. Fueled by data and digital technologies, our cutting‐edge science and manufacturing have the potential to transform the practice of medicine, turning the impossible into possible for millions of people around the world. Our Specialty care team focuses on developing therapies for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families, in the areas of rare blood disorders, neurology, oncology, and immunology.
Sun Pharma is a global pharmaceutical company with over 40 years of experience, manufacturing facilities across six continents, and a workforce of more than 41,000 people. The company provides high-quality, innovative medicines trusted by physicians and patients in over 100 countries. Its portfolio spans dermatology, ophthalmology, biologics, oncology, generics, branded medicines, and consumer health. In Canada, Sun Pharma has a commercial office in Mississauga and a manufacturing facility in Brampton, helping support access to medicines for patients across the country.

Join us at the OMNI King Edward Hotel in Toronto

Rising Stars in Dermatology Conference on Saturday, April 24, 2027

Subscribe to Canadian Dermatology Today

Canadian Dermatology Today provides clinicians with perspective and insight on the management of dermatological disease, while offering a forum to share real-world experience in the treatment and management of patients.

Published four times yearly in English, Canadian Dermatology Today is circulated to over 800 dermatologists, clinicians, nurses, and pharmacists across Canada. The journal features peer-reviewed articles that present robust clinical perspectives and practical insights on the management of dermatologic disease and the performance of aesthetic procedures.

About Catalytic Health

Founded in 2009, Catalytic Health is one of North America’s leading medical education agencies, one of the largest independent medical publishers, and an industry leader in innovative events, conferences, symposia, and services for the life sciences industry, reaching over 75,000 clinicians per year with its educational programs, services and platforms. Its proprietary Rising Stars brand provides educational and networking opportunities for early-to-practice physicians in multiple therapeutic areas, including dermatology, ophthalmology, cardiology, gastroenterology, hematology, and oncology.

To learn more, please visit catalytichealth.com

© 2026 All Rights Reserved.

Dr. Devani completed his dermatology residency at the University of Alberta, earning certification in both Canada and the United States. He has authored one textbook chapter, published 28 peer-reviewed manuscripts in scientific journals, and presented 62 abstracts at scientific congresses regionally, nationally, and internationally. Dr. Devani also conducts clinical trials in both adults and children, with participation in 125 studies as an investigator. He is the co-founder and codirector of Skin Health & Wellness Centre, Dermphi Centre, Dermphi Shop, and Dermatology Research Institute. His practice focuses exclusively on skin cancer and immune-mediated inflammatory diseases, especially atopic dermatitis and psoriasis, as well as alopecia areata and vitiligo.

Dr. Anastasiya Muntyanu is a Canadian and US board-certified dermatologist currently practicing in Toronto. She completed her medical school at the University of Ottawa and graduated from the University of Toronto Dermatology Residency Program. She is completing her PhD focused on studying environmental triggers of autoimmune and inflammatory skin diseases, including psoriasis, systemic sclerosis, and atopic dermatitis. She has over 40 publications in high-impact journals and has received numerous awards, including recognition from the Canadian Institutes of Health Research, Canadian Dermatology Association, and American Dermato-Epidemiology Network. 

During her residency, she was the co-chair of the Canadian Dermatology Association’s Resident and Fellow Society and served as a resident representative on numerous academic committees, for which she received the Resident Leadership Award and Resident Teaching Award from the Canadian Dermatology Association. Her clinical areas of interest include medical and surgical dermatology, with a focus on psoriasis, eczema, systemic sclerosis and morphea, and skin cancer. Her affiliations include Women’s College Hospital and Canadian Dermatology Center in Toronto.

Dr. Prajapati completed his dermatology residency at the University of Alberta, earning certification in both Canada and the United States. He then pursued an additional one-year fellowship in pediatric dermatology at Harvard Medical School. Dr. Prajapati has received 20 major awards at the regional and national levels, authored one textbook chapter, published 90 peer-reviewed manuscripts in scientific journals, and presented 147 abstracts at scientific congresses regionally, nationally, and internationally. 

He also conducts clinical trials in both adults and children, with participation in 116 studies as an investigator and/or member of the global data monitoring or steering committee. Dr. Prajapati is a Clinical Associate Professor at the University of Calgary, as well as co-founder and co-director of Skin Health & Wellness Centre, Dermphi Centre, Dermphi Shop, and Dermatology Research Institute. His practice focuses exclusively on skin cancer and immune-mediated inflammatory diseases, especially atopic dermatitis and psoriasis, as well as alopecia areata and vitiligo. He has also been appointed as a Councillor for the International Psoriasis Council.

Dr. Ringuet is a board-certified dermatologist practicing in Quebec City at the Centre de Recherche Dermatologique du Québec Métropolitain (CRDQ) and in Montreal at the McGill University Health Center (MUHC). He obtained a bachelor’s degree in biology before completing his medical training (MD) and dermatology residency at Laval University in Quebec City. During his medical training, he also completed a master’s degree in experimental medicine (MSc) in the field of skin bioengineering at the Centre de Recherche en Organogénèse Expérimentale de l’Université Laval (LOEX). 

Following his postgraduate studies, Dr. Ringuet has practiced with his team at the Centre de Recherche Dermatologique du Québec Métropolitain (CRDQ) since 2020 as a principal investigator and medical director. His research interests primarily include psoriasis and its variants, atopic dermatitis, vitiligo, and alopecia areata. He has served as a principal investigator for more than 50 clinical trials, resulting in a range of peer-reviewed publications, talks, and lectures.

Dr. Reetesh Bose is a board-certified dermatologist at The Ottawa Hospital and a faculty lecturer in the Division of Dermatology at the University of Ottawa. He completed his dermatology residency training at the University of Ottawa. He is an EDI committee member with the CDA, and Division of Dermatology Lead for EDI with The Ottawa Hospital. With numerous publications, his clinical and research interests include ethnodermatology, medical education, medical, surgical, and cosmetic dermatology. Dr. Bose serves as director of the Ottawa Skin of Colour Dermatology Clinic at The Ottawa Hospital and co-directs the Ottawa-Nunavut Dermatology Program.

Dr. Genest works at McGill University Health Center, where she heads Canada’s first university-based reproductive immunology clinic. She is also Director of the Reproductive Immunology Fellowship Program at McGill. Her clinical and research interests focus on reproductive immunology, including determining which patients may benefit from immunotherapy and identifying biomarkers of immune dysregulation to improve care for this vulnerable patient population. Clinically, she established Canada’s first university-based reproductive immunology clinic, which is now a reference centre in Quebec for the evaluation of complex patients with unexplained infertility or recurrent pregnancy loss. Since 2020, it has also been home to Canada’s only Reproductive Immunology Fellowship Program. In research, Dr. Genest is completing her PhD in Experimental Medicine. Her main project aims to develop a diagnostic test to detect patients with immune-mediated reproductive failure and determine which patients may benefit from immune therapies to improve their chances of conceiving or maintaining a pregnancy.

Dr. Annie Genois is a dermatologist based in Montreal, Canada. She completed her dermatology residency at the Université de Montréal in 2018, after previously earning a law degree.

She is co-owner of Clinique de dermatologie Rosemont, where she practices general dermatology, caring for both adult and pediatric patients, and provides phototherapy. In collaboration with the Centre de recherche Saint-Louis, she is actively involved in clinical research as a principal investigator and sub-investigator in numerous clinical trials.

Her main clinical interests include inflammatory dermatoses and dermoscopy.

Dr. Carolyn Jack (MDCM, PhD, FRCPC) is an Assistant Professor, Dermatology, at McGill University, a Scientist in the Infectious Diseases and Immunity in Global Health Program of the Research Institute of the McGill University Health Centre (MUHC), and an FRQS Clinical Research Scholar. Dr. Jack is also the founder and head of the MUHC Center of Excellence for Atopic Dermatitis, the first tertiary care centre in Canada dedicated to adult atopic dermatitis. 

Dr. Lemieux is a Clinical Associate Professor at the Université de Montréal. He completed his residency at the Université de Montréal, with a master’s degree in Experimental Medicine during his training. He also completed a fellowship in autoimmune blistering diseases at the national reference centre in Rouen, France. He has a specific interest in complex medical dermatology and currently practices at Sacré-Coeur Hospital in Montreal, where he is actively involved in resident teaching and research.

Dr. Elena Netchiporouk is an Assistant Professor of Dermatology and an FRQS Junior 1 clinician-scientist at McGill University Health Centre. She received her MD from the Université de Montréal and completed her dermatology residency and MSc in Experimental Medicine at McGill University. She co-directs the multidisciplinary skin fibrosis, urticaria/mastocytosis, and genodermatology clinics at the Montreal General Hospital of the McGill University Health Centre. Her research focuses on immune-mediated skin diseases and orphan dermatoses. Dr. Netchiporouk leads innovative research integrating epidemiology, machine learning, and bioinformatics to identify risk factors and improve management strategies for these conditions. Her work has been supported by prominent funding agencies, including the Canadian Institutes of Health Research (CIHR), Fonds de recherche du Québec – Santé (FRQS), Scleroderma Foundation, and Canadian Dermatology Foundation (CDF). She also serves as the Regional Director of the Canadian Dermatology Association. Dedicated to mentorship, she has trained numerous graduate students and actively practices dermatology in underserved communities.

Dr. Maxwell B. Sauder is an Assistant Professor in the Division of Dermatology at the University of Toronto. He is an onco-dermatologist at Princess Margaret Cancer Centre and the Research Director at Toronto Research Centre. He earned his Doctor of Medicine degree at McMaster University, completed his residency in dermatology at the University of Ottawa, and completed fellowship training in Cutaneous Oncology at Harvard Medical School.

Dr. Sibbald is a dermatologist who completed her residency training at the University of Toronto and is board certified in Canada and the United States. She completed fellowship training in pediatric dermatology at the Children’s Hospital of Philadelphia. She holds an MSc in Epidemiology from the London School of Hygiene & Tropical Medicine and a BSc Ph.M. from the University of Toronto. She is a staff physician with research and clinical activities at the Hospital for Sick Children and recently joined the pyoderma gangrenosum clinic at Women’s College Hospital. She is an Assistant Professor at the University of Toronto in the Department of Pediatrics, with a cross-appointment to the Department of Medicine. Her clinical interests are broad and include alopecia, morphea, and laser treatment of vascular lesions.

Dr. Danya Traboulsi is a board-certified dermatologist in both Canada and the United States and is appointed as a Clinical Assistant Professor at the Cumming School of Medicine, University of Calgary. She practices general medical, surgical, and cosmetic dermatology at Skin Health & Wellness Centre. She completed her Biological Sciences degree at the University of Calgary and medical school at Queen’s University, where she was awarded the Franklin & Helene Bracken Scholarship in Medicine for students with the highest academic standing. She is actively involved in education and sits on the Residency Program Committee for the University of Calgary Dermatology Residency Program. Dr. Traboulsi is also involved in research, has published articles in leading dermatology journals, and participates in clinical trials.

Dr. Ron Vender is a dermatologist practicing in Hamilton, Ontario, where he is the founder and director of Dermatrials Research Incorporated and Venderm Consulting Inc. He has served as principal investigator in more than 120 clinical trials, enrolling over 1,000 participants. He is an Associate Clinical Professor in the Department of Medicine, Division of Dermatology, at McMaster University and serves on the editorial boards of several high-impact journals. Dr. Vender is one of a small number of Canadians elected to the International Psoriasis Council and is a member of the Canadian Professors of Dermatology and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis. He represents Canada on multiple global educational steering committees and international advisory boards. He has authored over 180 peer-reviewed publications, including work published in leading journals such as The Lancet and The New England Journal of Medicine. His posters, abstracts, and lectures have been presented internationally across five continents and in more than 50 countries.